Lv4
610 积分 2021-07-07 加入
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
14小时前
已完结
Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma
17天前
已完结
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
2个月前
已完结
Von Hippel-Lindau protein signalling in clear cell renal cell carcinoma
2个月前
已完结
Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
2个月前
已完结
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
3个月前
已完结
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
4个月前
已完结
Senaparib as first-line maintenance therapy in advanced ovarian cancer: a randomized phase 3 trial
5个月前
已完结
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer
6个月前
已完结
De-Escalation Strategies With Immune Checkpoint Blockers in Non-Small Cell Lung Cancer: Do We Already Have Enough Evidence?
6个月前
已完结
皖公网安备34019202002308
